Delayed
Nasdaq
03:53:25 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
24
USD
|
+7.29%
|
|
+26.28%
|
-10.83%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,338
|
12,884
|
10,168
|
2,786
|
3,283
|
2,737
|
-
|
-
|
Enterprise Value (EV)
1 |
7,338
|
11,896
|
10,370
|
2,912
|
3,255
|
2,990
|
3,218
|
3,399
|
P/E ratio
|
-93
x
|
-49.6
x
|
-25
x
|
-4.24
x
|
-6.32
x
|
-6.96
x
|
-7.66
x
|
-8.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
34.2
x
|
44.9
x
|
27.2
x
|
6.2
x
|
5.82
x
|
4.03
x
|
3.38
x
|
2.78
x
|
EV / Revenue
|
34.2
x
|
41.5
x
|
27.8
x
|
6.48
x
|
5.77
x
|
4.4
x
|
3.98
x
|
3.46
x
|
EV / EBITDA
|
-103
x
|
-140
x
|
-26.7
x
|
-5.84
x
|
-7.46
x
|
-9.82
x
|
-11.3
x
|
-11.7
x
|
EV / FCF
|
-111
x
|
-84.9
x
|
-36.5
x
|
-7.53
x
|
-9.42
x
|
-10.1
x
|
-12.3
x
|
-14.8
x
|
FCF Yield
|
-0.9%
|
-1.18%
|
-2.74%
|
-13.3%
|
-10.6%
|
-9.88%
|
-8.12%
|
-6.78%
|
Price to Book
|
9.23
x
|
9.95
x
|
15.8
x
|
46.4
x
|
20.7
x
|
-27.7
x
|
-8.39
x
|
-5.84
x
|
Nbr of stocks (in thousands)
|
93,906
|
99,972
|
101,656
|
102,436
|
121,380
|
122,369
|
-
|
-
|
Reference price
2 |
78.14
|
128.9
|
100.0
|
27.20
|
27.05
|
22.37
|
22.37
|
22.37
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
214.4
|
286.7
|
373.7
|
449.5
|
563.9
|
679.6
|
808.8
|
983.1
|
EBITDA
1 |
-70.96
|
-85.18
|
-388.7
|
-498.9
|
-436.3
|
-304.6
|
-284.5
|
-289.6
|
EBIT
1 |
-82.37
|
-255
|
-411
|
-544.4
|
-564.7
|
-375.2
|
-352.8
|
-283.1
|
Operating Margin
|
-38.42%
|
-88.92%
|
-110%
|
-121.1%
|
-100.14%
|
-55.21%
|
-43.62%
|
-28.8%
|
Earnings before Tax (EBT)
1 |
-69.72
|
-245.9
|
-384.5
|
-653.4
|
-478.8
|
-382.6
|
-351.4
|
-327.6
|
Net income
1 |
-75.65
|
-253.8
|
-405.7
|
-654.6
|
-479.4
|
-381.1
|
-349
|
-322.5
|
Net margin
|
-35.29%
|
-88.51%
|
-108.57%
|
-145.61%
|
-85.02%
|
-56.07%
|
-43.15%
|
-32.8%
|
EPS
2 |
-0.8400
|
-2.600
|
-4.000
|
-6.410
|
-4.280
|
-3.216
|
-2.921
|
-2.570
|
Free Cash Flow
1 |
-65.85
|
-140.1
|
-284.1
|
-386.9
|
-345.5
|
-295.3
|
-261.4
|
-230.4
|
FCF margin
|
-30.72%
|
-48.86%
|
-76.02%
|
-86.07%
|
-61.26%
|
-43.45%
|
-32.32%
|
-23.43%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
108.1
|
96.1
|
109.1
|
117.4
|
126.9
|
128.7
|
137.2
|
143
|
155.1
|
168.5
|
162.1
|
169.1
|
182
|
186.3
|
195.6
|
EBITDA
1 |
-92.12
|
-111.6
|
-120
|
-122.6
|
-133.3
|
-123.4
|
-108.1
|
-101.8
|
-102.9
|
-88.48
|
-77.48
|
-77.09
|
-78.19
|
-80.7
|
-76.69
|
EBIT
1 |
-98.21
|
-123.3
|
-130.3
|
-144.6
|
-146.1
|
-134.1
|
-119.6
|
-113.5
|
-197.5
|
-99.68
|
-97.85
|
-93.92
|
-92.3
|
-99.24
|
-92.12
|
Operating Margin
|
-90.84%
|
-128.34%
|
-119.4%
|
-123.16%
|
-115.15%
|
-104.15%
|
-87.22%
|
-79.38%
|
-127.38%
|
-59.16%
|
-60.35%
|
-55.55%
|
-50.72%
|
-53.27%
|
-47.1%
|
Earnings before Tax (EBT)
1 |
-72.3
|
-123.3
|
-229
|
-161.9
|
-139.3
|
-133.3
|
-72.28
|
-85.61
|
-187.6
|
-114.6
|
-101.3
|
-98.35
|
-97.67
|
-98.92
|
-97.57
|
Net income
1 |
-90.91
|
-123.2
|
-229.4
|
-162
|
-139.9
|
-133.5
|
-72.77
|
-86.1
|
-187
|
-115
|
-97.82
|
-94.3
|
-91.53
|
-94.19
|
-91.14
|
Net margin
|
-84.09%
|
-128.23%
|
-210.21%
|
-137.98%
|
-110.28%
|
-103.74%
|
-53.06%
|
-60.2%
|
-120.63%
|
-68.24%
|
-60.33%
|
-55.77%
|
-50.3%
|
-50.56%
|
-46.6%
|
EPS
2 |
-0.8900
|
-1.210
|
-2.250
|
-1.580
|
-1.360
|
-1.300
|
-0.6700
|
-0.7300
|
-1.580
|
-0.9400
|
-0.7989
|
-0.7685
|
-0.7468
|
-0.7678
|
-0.7443
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/23/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/9/23
|
8/3/23
|
11/6/23
|
2/22/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
202
|
126
|
-
|
253
|
481
|
661
|
Net Cash position
1 |
-
|
989
|
-
|
-
|
28.7
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.5198
x
|
-0.2529
x
|
-
|
-0.8381
x
|
-1.709
x
|
-2.283
x
|
Free Cash Flow
1 |
-65.9
|
-140
|
-284
|
-387
|
-345
|
-295
|
-261
|
-230
|
ROE (net income / shareholders' equity)
|
-11.8%
|
-24.2%
|
-41.7%
|
-186%
|
-438%
|
-122%
|
-48.6%
|
-9%
|
ROA (Net income/ Total Assets)
|
-9.76%
|
-15.7%
|
-18.1%
|
-34.3%
|
-28.2%
|
-15.7%
|
-16.6%
|
-12.4%
|
Assets
1 |
775
|
1,617
|
2,238
|
1,907
|
1,698
|
2,435
|
2,065
|
2,591
|
Book Value Per Share
2 |
8.470
|
13.00
|
6.340
|
0.5900
|
1.300
|
-0.8100
|
-2.670
|
-3.830
|
Cash Flow per Share
2 |
-0.5200
|
-1.070
|
-2.060
|
-3.030
|
-2.900
|
-1.970
|
-1.170
|
0.4400
|
Capex
1 |
18.7
|
36.2
|
75
|
77.5
|
20.5
|
44.5
|
51.2
|
45.8
|
Capex / Sales
|
8.73%
|
12.62%
|
20.08%
|
17.23%
|
3.63%
|
6.54%
|
6.33%
|
4.66%
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
22.37
USD Average target price
37.39
USD Spread / Average Target +67.14% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.83% | 2.74B | | -24.84% | 9.87B | | -12.92% | 2.24B | | -17.99% | 1.63B | | +62.21% | 1.39B | | +24.08% | 772M | | -4.59% | 760M | | -22.14% | 516M | | -0.60% | 310M | | +6.47% | 219M |
Bio Diagnostics & Testing
|